Piper Sandler: 'We believe now is the time to own Oruka Therapeutics (ORKA)'

October 7, 2026 9:15 AM EDT Send to a Friend
Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $180.00 price target on Oruka Therapeutics (NASDAQ: ORKA).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login